Latest Accounting News

Matrix Composites & Engineering Ltd delivered a solid FY25 with $74.8 million revenue driven by subsea buoyancy demand, underpinning a $5.0 million underlying EBITDA. The company’s $57 million subsea order book and recent $45 million SURF awards set a promising stage for FY26 growth.

Matrix Composites & Engineering Ltd posted a 12.1% revenue decline to $74.77 million for FY25, reporting a net loss of $2.2 million as subdued drilling buoyancy markets weighed on results despite strong growth in subsea buoyancy products.

Wisr Limited has returned to profitability in FY25, driven by a doubling of loan originations and improved margins, setting the stage for ambitious growth in FY26.

EBOS Group Limited reported a 7% drop in revenue and a 21% fall in net profit for FY2025, reflecting ongoing cost pressures and restructuring impacts. The company declared a final dividend, signaling cautious optimism despite the earnings setback.

RPMGlobal completes its transition to a pure-play software company, reporting robust FY25 results driven by subscription revenue growth and a $63.6 million Advisory divestment. The company projects significant margin expansion and revenue growth in FY26 backed by a $200 million contract backlog.

Dubber Corporation Limited will record a significant non-cash impairment charge in FY25 following the loss of a major customer contract with Virgin Media O2, impacting its intangible assets from a prior acquisition.

CVC Limited reports a stable FY2025 profit alongside a robust landbank poised for significant value uplift, targeting a net tangible asset per share of $5.75 through strategic rezoning and development.

Ironbark Capital Limited reported a 17.6% increase in net profit for FY2025, driven by higher investment income and realised gains, alongside a raised fully franked dividend and an extended share buy-back program.

Microba Life Sciences reported a 30% increase in revenue to $15.7 million for FY25, driven by strong growth in its core microbiome diagnostic products and successful UK market expansion. Despite narrowing its net loss to $14.9 million, the company is focused on scaling diagnostics adoption and achieving break-even in FY26.

Elanor Commercial Property Fund reported a statutory loss for FY25 but delivered a 6.9% rise in Funds from Operations, while rejecting an unsolicited takeover offer from the Lederer Group.

Starpharma reports a significant 183% jump in FY25 revenue to $4.9 million, alongside a 31% reduction in losses and a solid cash position of $15.4 million. The biotech firm’s progress underscores growing momentum in its dendrimer technology pipeline.

Elanor Commercial Property Fund reported a $5.4 million statutory loss for FY25 despite a slight increase in Funds from Operations, while navigating a strategic capital raise and an unsolicited takeover offer from the Lederer Group.